Posted by Michael Wonder on 13 Sep 2016
Aptinyx receives FDA fast track designation for development of NYX-2925 as treatment for neuropathic pain associated with diabetic peripheral neuropathy
13 September 2016 - Data from pre-clinical investigation of NYX-2925 to be presented at 16th World Congress on Pain on September 30.
Aptinyx today announced its intention to develop its lead compound, NYX-2925, as a treatment for neuropathic pain associated with diabetic peripheral neuropathy.
The U.S. FDA has designated the investigation of NYX-2925 in the indication as a fast track development program. The FDA’s Fast Track program was implemented to expedite the development and regulatory review of therapeutic programs that seek to address significant unmet medical needs.
